The development led to a surge in the share price of the pharma major, which closed 8.13 per cent higher at Rs 528.20 on BSE.
In a notification on its website, the US Food and Drug Administration said it has issued Voluntary Action Indicated (VAI) status to the company's plant.
According to the USFDA, VAI means "Voluntary Action Indicated. Objectionable conditions were found but the problems do not justify further regulatory action..."
In February, the USFDA had issued three observations after inspecting the facility. The company had said it was preparing the response to the observations.
This follwed inspection of the facility in September 2014 by FDA inspectors.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)